Immunologic response to cis-platinum in ovarian malignancies
Li, P.W.
Zhonghua Fu Chan Ke Za Zhi 20(6): 371-372
1985
ISSN/ISBN: 0529-567X PMID: 3833499 Document Number: 249940
Document emailed within 1 workday
Related Documents
Linasmita, V.; Wilailak, S.; Srisupundit, S.; Tangtrakul, S.; Bullangpoti, S.; Israngura, N. 1998: Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital Journal of the Medical Association of Thailand 81(1): 10-16Gadducci, A.; Cosio, S.; Fanucchi, A.; Tanganelli, L.; Conte, P.F.; Cristofani, R.; Genazzani, A.R. 2003: Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma? European Journal of Gynaecological Oncology 24(5): 405-410
Sawada, M.; Ozaki, M.; Taniguchi, H.; Tateishi, R.; Mori, Y.; Mino, K. 1988: Effect of a newly developed platinum compound cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II), on human ovarian tumors transplanted into nude mice Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(4 Part 1): 637-641
Huang, H.; Lian, L.; Huang, R. 1995: Response of ovarian endodermal sinus tumor to combination chemotherapy with cis-platinum, vincristine and bleomycin or vincristine, actinomycin and cyclophosphamide Zhonghua Fu Chan Ke Za Zhi 30(5): 265-269
Kozłowski, H.; Hrabowska, M.; Walkowicz, E. 1979: Analysis of cellular immunologic response in the stroma of early embryonic ovarian tumors of the gonadoblastoma type Patologia Polska 30(2): 229-237
Reed, E.; Parker, R.J.; Gill, I.; Bicher, A.; Dabholkar, M.; Vionnet, J.A.; Bostick-Bruton, F.; Tarone, R.; Muggia, F.M. 1993: Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies Cancer Research 53(16): 3694-3699
Endo, K.; Akamatsu, K.; Matsumoto, T.; Morikawa, K.; Koizumi, M.; Mitsui, H.; Koizumi, K. 1992: Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice Anticancer Research 12(1): 49-58
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Tangjitgamol, S.; Mamusirinitaya, S.; Leelahakorn, S.; Thawaramara, T.; Pataradool, K.; Suekwatana, P.; Sittidilokratna, K. 2005: Efficacy of platinum plus cyclophosphamide in patients with epithelial ovarian cancer Journal of the Medical Association of Thailand 88(9): 1172-1181
Martoni, A.; Bellucco, A.; Canova, N.; Pannuti, F. 1989: Four-year analysis of platinum and anthracycline combination for ovarian cancer Oncology 46(2): 109-116
Mandic, A.; Vujkov, T.; Malbasa, Z. 2003: Paclitaxel or docetaxel combined with platinum in advanced ovarian cancer? Journal of BUON: Official Journal of the Balkan Union of Oncology 8(1): 19-22
Covens, A.; O'Connell, G.; Rusthoven, J.; Mazurka, J. 1992: Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer European Journal of Gynaecological Oncology 13(2): 125-130
Bliumenberg, A.G.; Gorbacheva, L.B.; Gorbunova, V.A.; Kozachenko, V.P.; Lankin, V.Z. 1996: Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives Biulleten' Eksperimental'noi Biologii i Meditsiny 122(12): 651-654
Usui, N. 2019: Hematologic Malignancies/Pediatric Malignancies Current Guidelines of Clinical Management and Drug Therapy for Hematological Malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(5): 859-861
Welch, R.S.; James, R.D.; Wilkinson, P.M.; Belli, F.; Cowan, R.A. 1995: Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer Cancer Journal from Scientific American 1(4): 261-266
Scotto, V.; Sbiroli, C. 1991: Weekly cis-platinum as third line chemotherapy in advanced ovarian carcinoma. Phase Ii study European Journal of Gynaecological Oncology 12(1): 51-53
Tarraza, H.M.; Muntz, H.G.; De Cain, M.; Jones, M.A. 1993: Cervical metastases in advanced ovarian malignancies European Journal of Gynaecological Oncology 14(4): 274-278
Mueller, W.K.; Handschumacher, R.; Wade, M.E. 1971: Serum haptoglobin in patients with ovarian malignancies Obstetrics and Gynecology 38(3): 427-435
Ezcurdia, L.; Jovtis, S.L.; Mickiewicz, E.; Temperley, G.; Rondinón, M.; Blajman, C.; Cóppola, F.S.; Lewi, D.; Cazap, E.; Breier, S.; Fasce, H.; Fein, L.; Polera, J.; Triguboff, E.; Uranga, G.; Pasccón, G.; Luchina, A.M.; Martínez, C.A.; Politi, P.M.; Rubio, G.; Alvarez, A.M. 1997: Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group Seminars in Oncology 24(5 Suppl. 15): S15
Sawada, M.; Ozaki, M.; Hongo, J.; Hirota, Y.; Inagaki, M.; Taniguchi, H.; Tateishi, R.; Mori, Y. 1987: Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(3 Part 1): 693-698